Amgen (AMGN) is attracting renewed demand following a retracement within a strong uptrend. The stock continues to exhibit a bullish structure characterized by higher highs and higher lows, with price trading above the aligned 20-day and 50-day moving averages, reinforcing the underlying positive momentum. The renewed interest also reflects a broader defensive rotation into healthcare stocks amid heightened geopolitical risks stemming from tensions involving the United States, Israel, and Iran. Amgen is a biotechnology company engaged in the discovery, development, manufacture, and marketing of human therapeutics. The company has a market capitalization of approximately $203.57 billion and is one of the leading firms in the global biotechnology industry. Amgen is widely regarded as a wide economic moat company, supported by strong innovation capabilities, biologics expertise, and a robust portfolio of therapeutics. Over the last four quarters, the company has demonstrated consistent growth in both revenue and earnings per share (EPS). Profitability metrics remain strong, with return on equity (ROE), return on invested capital (ROIC), and net profit margin averaging approximately 98%, 11%, and 20%, respectively, during the same period. From a balance sheet perspective, the company maintains adequate liquidity, with a current ratio of about 1.1x, although leverage remains relatively elevated with a debt-to-equity ratio of approximately 6.4x. Overall, Amgen’s strong market position and defensive sector characteristics continue to support investor interest during periods of macroeconomic and geopolitical uncertainty. NASDAQ:AMGN

Team, We are not buying now. Price is still trading below major descending resistance (R). As long as we are below R, the structure remains under pressure. ✅ What We Are Waiting For We only buy if: Price breaks above the descending resistance (R) A candle closes clearly above it We see strength (no immediate rejection wick) Ideally: a small pullback that holds above R No breakout = no trade. 🟢 Entry Plan (After Confirmation) Once price: Breaks above R Retests and holds

Amgen spent a quarter consolidating near record highs, and now it may have broken out. The first pattern on today’s chart is the surge on February 4 after earnings beat estimates. The pharmaceutical giant pulled back to hold a 50 percent retracement of the move, potentially confirming its upward trajectory. Second, the 50-day simple moving average (SMA) crossed above the 100-day SMA in November and has expanded since, which may confirm its long-term direction has grown more bullish. Third, the 8-day exponential moving average (EMA) is above the 21-day EMA. MACD is also rising. Those signals could reflect short-term bullishness. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. Learn more here about TradingView’s Broker of the Year! Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.

The #UPC Court of Appeal confirmed the validity of Amgen's key Repatha patent (EP 797), securing its market lead against Sanofi. This massive legal victory clears the path for infringement proceedings and could potentially unlock value leading to a 50% stock increase! @Amgen: The Repatha shield is strong! @Sanofi: The battle continues. #Amgen #Repatha #Biotech #StockMarket #PatentLaw NASDAQ:AMGN NASDAQ:SNY

Amgen rallied sharply last month, and some traders may see more upside in the drug maker. The first pattern on today’s chart is the advance after earnings and revenue beat estimates on November 4. Such a move may reflect improved sentiment. Second is the $337.38 level, AMGN’s previous record-high closing price from 2024. The shares have remained near (and often above) that level for more than three weeks. Is a breakout next? Third is the series of higher lows as prices challenge resistance. That ascending triangle is a potentially bullish continuation pattern. Next, the 8-day exponential moving average (EMA) has remained above the 21-day EMA. The 50-day simple moving average (SMA) also had a “golden cross” above the 200-day SMA last month. Those signals may suggest short- and long-term directions have gotten more positive. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.

1. Technical Analysis AMGN has formed a bullish pennant pattern after a strong upside rally. This compression typically acts as a continuation setup, suggesting that buyers are preparing for another push higher—if the major resistance gives way. Key Resistance • $346.7 → Major multi-year resistance Bullish Scenario If AMGN breaks above 346.7: • Target 1: $360 • Target 2: $370 • Target 3: $385 Bullish catalysts: • Strong prior momentum • Bullish Pennant continuation pattern • Trading well above the 50-day SMA Bearish Scenario If price breaks below the pennant support: • Support 1: $330 • Support 2: $318 • Support 3: 50-day SMA (~$308) Suggested Stop-Loss For short-term traders: • Stop-Loss: A confirmed break below $330 (A close below 330 indicates weakness and invalidation of the pennant.) For swing/mid-term traders: • Stop-Loss (safer): $318 (Losing this level breaks the broader bullish structure.) 2. Fundamental Snapshot Positives • Strong revenue performance in specialty therapeutics • Recent earnings beat expectations • Healthy cash flow and margins • Expanding R&D pipeline and new partnerships Risks • Intense competition within biotech • Price-pressure risks • Regulatory and FDA-related uncertainties Summary: The fundamentals remain strong and support the bullish technical structure unless major negative catalysts emerge. 3. Final Summary AMGN is sitting at a critical inflection point. A breakout above 346.7 could trigger a new bullish leg, while weakness below 330 activates the stop-loss for short-term traders.

======= Volume ======= - Healthy ========== Price Action ========== - Bullish flag spotted - Supported above $310 - Gapped up from a near 6 month ascending triangle ================= Technical Indicators ================= - Ichimoku >>> price above cloud >>> Green kumo expanding >>> Tenken - Above clouds, crossed Lagging & pointing up >>> Kijun - Above clouds, crossed Lagging & pointing up >>> Chiku - Above clouds, Conv, Base & pointing up slightly ========= Oscillators ========= >>> MACD - bullish >>> DMI - bullish >>> StochRSI - bullish, around overbought region ========= Conclusion ========= >>> Ichimoku overall - bullish >>> Oscillators overall - remains bullish >>> Additional comments - bullish trend remains intact with weak selling pressure withing the bull flag ========= Trade Plan ========= - short to long term breakout swing - price may reverse at current level, to enter spot or wait for pullback at entry 2. - Entries and exits depends on your time horizon and risk management. ========= Positions ========= Entry 1 - $324 Entry 2 - $310 Stop - $293 Exit 1 - $334 Exit 2 - $343 Exit 3 - $353 Exit 4 - $380 Exit 5 - $410

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This will likely pump over 300$ Its pushing over vwap now and 320$ seems like a decent tp area TP1 304$ TP2 320$ TP3 344$

======= Volume ======= - neutral ========== Price Action ========== - rounding bottom recently - Ascending triangle noticed ================= Technical Indicators ================= - Ichimoku >>> price above cloud >>> Green kumo budding >>> Tenken - above clouds and pointing up >>> Chiku - within clouds and pointing up slightly >>> Kijun - Above clouds and pointing up ========= Oscillators ========= - MACD still bullish - DMI neutral - StochRSI, still bullish ========= Conclusion ========= - short to long term breakout swing - price may reverse at current level, to enter spot or wait for pullback at entry 2. ========= Positions ========= Entry - $298 Entry 2 - $286 Stop - $268 Exit 1 - $315 Exit 2 - $354 Exit 3 - $385 Exit 4 - $419 Exit 5 - $470